FDA Approves Asundexian for Secondary Stroke Prevention

Recovered source-gap item: Bayer announced November 10 US FDA approval of asundexian 50 mg with antiplatelet therapy after non-cardioembolic ischemic stroke or high-risk transient ischemic attack. The same drug had already been approved in…




